3-Hydroxy-N-(propan-2-yl)naphthalene-2-carboxamide | 59192-04-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-Hydroxy-N-(propan-2-yl)naphthalene-2-carboxamide
• 英文别名: 3-hydroxy-N-propan-2-ylnaphthalene-2-carboxamide
• CAS: 59192-04-0
• 化学式: C₁₄H₁₅NO₂
• mdl: MFCD08897670
• 分子量: 229.27
• InChiKey: SZROYGJENDVJOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.214
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS
  申请人：CARLINI Rina

  公开号：US20100035172A1

  公开（公告）日：2010-02-11

  A nanoscale pigment particle composition includes an organic benzimidazolone pigment, and a sterically bulky stabilizer compound, wherein the benzimidazolone pigment associates non-covalently with the sterically bulky stabilizer compound that is an alkylated-benzimidazolone compound; and the presence of the associated stabilizer limits the extent of particle growth and aggregation, to afford nanoscale pigment particles.

  一种纳米级颜料粒子组合物包括有机苯并二唑酮颜料和立体障碍稳定剂化合物，其中苯并二唑酮颜料与立体障碍稳定剂化合物非共价结合，该化合物是烷基化苯并二唑酮化合物；并且所述稳定剂的存在限制了颗粒生长和聚集的程度，从而得到纳米级颜料粒子。
• Methods of making nanosized particles of benzimidazolone pigments
  申请人：Xerox Corporation

  公开号：EP2290013A2

  公开（公告）日：2011-03-02

  Nanoscale particles of benzimidazolone pigments are made by providing one or more organic pigment precursor(s) to a benzimidazolone pigment, providing a solution or suspension of a sterically bulky stabilizer compound that associates non-covalently with a benzimidazolone moiety on one of the pigment precursors, wherein the sterically bulky stabilizer compound is selected from the group consisting of substituted pyridine derivatives, alkylated benzimidazolone compounds, alkylated derivatives of aromatic acids, and mixtures thereof, and carrying out a coupling reaction to form a benzimidazolone pigment composition, whereby one or more functional moieties on the benzimidazolone pigment is non-covalently associated with the sterically bulky stabilizer, so as to limit an extent of particle growth and aggregation and results in nanoscale pigment particles.

  苯并咪唑酮颜料的纳米级颗粒是通过提供一种或多种苯并咪唑酮颜料的有机颜料前体，提供与颜料前体之一上的苯并咪唑酮分子非共价结合的立体笨重稳定剂化合物的溶液或悬浮液制成的，其中立体笨重稳定剂化合物选自由取代吡啶衍生物组成的组、烷基化苯并咪唑酮化合物、芳香族酸的烷基化衍生物及其混合物组成的组，并进行偶联反应以形成苯并咪唑酮颜料组合物，其中苯并咪唑酮颜料上的一个或多个官能团与立体笨重稳定剂非共价地结合，从而限制颗粒的生长和聚集程度，并形成纳米级颜料颗粒。
• METHODS OF MAKING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS
  申请人：CARLINI Rina

  公开号：US20100004360A1

  公开（公告）日：2010-01-07

  Nanoscale particles of benzimidazolone pigments are made by providing one or more organic pigment precursor(s) to a benzimidazolone pigment, providing a solution or suspension of a sterically bulky stabilizer compound that associates non-covalently with a benzimidazolone moiety on one of the pigment precursors, wherein the sterically bulky stabilizer compound is selected from the group consisting of substituted pyridine derivatives, alkylated benzimidazolone compounds, alkylated derivatives of aromatic acids, and mixtures thereof, and carrying out a coupling reaction to form a benzimidazolone pigment composition, whereby one or more functional moieties on the benzimidazolone pigment is non-covalently associated with the sterically bulky stabilizer, so as to limit an extent of particle growth and aggregation and results in nanoscale pigment particles.
• NONPOLAR LIQUID AND SOLID PHASE CHANGE INK COMPOSITIONS COMPRISING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS
  申请人：CARLINI Rina

  公开号：US20100300326A1

  公开（公告）日：2010-12-02

  An ink composition, such as a nonpolar liquid or phase change (solid) ink composition, that includes a non-polar carrier, and a nanoscale pigment particle composition. The nanoscale pigment particle composition includes a benzimidazolone pigment and a sterically bulky stabilizer compound, which is an alkylated-benzimidazolone compound, associated non-covalently with the benzimidazolone pigment. The presence of the associated stabilizer limits an extent of particle growth and aggregation, to afford nanoscale pigment particles.
• MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT
  申请人：The University of Kansas

  公开号：US20170144965A1

  公开（公告）日：2017-05-25

  A pharmaceutical composition can include: a marmelin analog compound, and a pharmaceutically acceptable carrier having the compound. The compound can be present in a therapeutically effective amount to treat or inhibit a disease state. The disease state can be cancer. The cancer can be selected from brain cancers, head and neck cancers, thyroid cancers, gastrointestinal cancers, esophageal cancers, stomach cancers, pancreatic cancers, liver cancers, colo-rectal cancers, lung cancers, kidney cancers, prostate cancers, bladder cancers, testicular cancers, breast cancers, ovarian cancers, cervical cancers, and melanomas. The carrier includes a cyclodextrin, which may form a complex with the compound. The compounds and compositions can be used to treat or inhibit progression of cancers. Colorectal, bladder, and prostate cancers are examples of some of the cancers that can be treated with the marmelin analog compounds.